Definium Therapeutics: 3 Key Takeaways for Long-Term Investors
Two encouraging changes from five patients hint at a pipeline beyond depression and anxiety, but the early-stage data leaves open whether DT402 can carry that weight.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.